| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | BSAP |
| Entrez GeneID | 5079 |
| clone | 1A7 |
| WB Predicted band size | 45kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human PAX5 (AA: 235-382) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
1. **"PAX5 Antibodies in the Diagnosis of B-Cell Neoplasms" by D.B.Y. Tsujimoto et al.**
- 摘要：探讨PAX5抗体在B细胞肿瘤(如B-ALL和弥漫大B细胞淋巴瘤)中的诊断价值，强调其作为B细胞特异性标志物的敏感性和特异性。
2. **"Comparative Study of PAX5 Antibodies in Immunohistochemistry" by C.J. Hung & L.R. Patel**
- 摘要：比较不同克隆PAX5抗体的染色性能，发现克隆24/PAX5在福尔马林固定组织中表现最佳，适用于鉴别B细胞淋巴瘤与非B细胞肿瘤。
3. **"PAX5 Expression in Classic Hodgkin Lymphoma" by M.L. Hans et al.**
- 摘要：分析PAX5在经典型霍奇金淋巴瘤中的弱表达模式，支持其用于区分CHL与PAX5阴性的T细胞淋巴瘤及间变性大细胞淋巴瘤。
4. **"PAX5 as a Lineage Marker in Mixed-Phenotype Acute Leukemia" by S.E. Bhojwani et al.**
- 摘要：研究PAX5抗体在混合表型急性白血病(MPAL)中的表达，证实其有助于识别伴B系分化的病例，指导临床分类与治疗。
(注：上述文献为示例，实际引用时请核实真实来源及准确性。)
**Background of PAX5 Antibody**
PAX5. a member of the PAX (paired box) transcription factor family, is critical for B-cell development and commitment. It regulates genes involved in B-cell receptor signaling, adhesion, and migration, ensuring proper differentiation and function. PAX5 is expressed during early B-cell ontogeny and persists in mature B-cells but is absent in plasma cells.
In diagnostic pathology, PAX5 antibodies are widely used as immunohistochemical (IHC) markers to identify B-cell lineage in malignancies. PAX5 expression is retained in most B-cell neoplasms, including B-acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphomas (NHLs). Its nuclear staining pattern helps distinguish B-cell tumors from T-cell or myeloid malignancies. PAX5 is particularly valuable in differentiating classical Hodgkin lymphoma (cHL), where PAX5 is weakly expressed in Hodgkin-Reed-Sternberg (HRS) cells, from other large B-cell lymphomas.
PAX5 antibodies target the N-terminal DNA-binding domain of the protein. Loss of PAX5 expression or mutations are linked to B-cell maturation arrest and leukemogenesis, underscoring its role as a tumor suppressor in some contexts. However, aberrant PAX5 activity can also drive oncogenic pathways in specific cancers.
Research and clinical applications rely on PAX5 antibodies for studying B-cell biology, disease mechanisms, and refining diagnostic accuracy in hematopathology. Its specificity makes it a cornerstone in panels alongside CD20. CD79a, and other markers.
×
